Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.52 |
| ▸ | BCR | P11274 | 14/20 | 0.52 |
| ▸ | KIT | P10721 | 8/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.52 |
| ▸ | CSF1R | P07333 | 4/20 | 0.52 |
| ▸ | ABL2 | P42684 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | LCK | P06239 | 3/20 | 0.52 |
| ▸ | FYN | P06241 | 3/20 | 0.52 |
| ▸ | LYN | P07948 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.52 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
| ▸ | NQO2 | P16083 | 3/20 | 0.52 |
| ▸ | EPHA8 | P29322 | 3/20 | 0.52 |
| ▸ | FRK | P42685 | 3/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.52 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.52 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
| ▸ | FGR | P09769 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524139 | 0.95 | ABL1 (0.57) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL4942076 | 0.88 | ABL1 (0.49) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL6359358 | 0.86 | ABL1 (0.70) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL5201864 | 0.82 | ABL1 (0.64) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL717503 | 0.78 | NPC1 (0.64) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL717173 | 0.76 | ABL1 (0.88) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL717184 | 0.75 | ABL1 (0.87) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL716308 | 0.75 | ABL1 (0.67) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL6359361 | 0.75 | ABL1 (0.58) | ABL1BCRKITPDGFRBCSF1R | |
| SCHEMBL6279931 | 0.74 | LCK (0.69) | ABL1BCRKITPDGFRBCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | AB SCIENCE | 2008-06-19 | — | — | US | disclosed |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | AB SCIENCE (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | MOUSSY ALAIN | 2007-10-25 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | KIT, CPA3, CMA1 | ABL1 1013/4885BCR 3062/4885KIT 1/4885 |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | ABL1 419/4885BCR 2636/4885KIT 1/4885 |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | KIT, JAK3, MAP3K3 | ABL1 5/4885BCR 349/4885KIT 1/4885 |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | KIT, CPA3, CMA1 | ABL1 176/4885BCR 1450/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.